A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein

Thrombosis Research

Volumn 113, Issue 3-4, 2004, Pages 243-250

  Calabrese, Graciela C ^a   Alberto, María F ^b   Tubio, Rosario ^a   Marani, Mariela M ^a   Fernández De Recondo, Marta E ^a   Lazzari, María ^b   Recondo, Eduardo F ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c Ciudad Universitaria ^*  (Argentina)

Author keywords

antithrombin; AT; C1; Complement system; Con A; Concanavalin A; Dermatan sulfate; DS; free Dermatan sulfate; free DS; GAG; glycosaminoglycan; Heparin cofactor II; HS; Molecular interactions; the first protein complex of the complement system

Indexed keywords

CALCIUM ION; DERMATAN SULFATE; FIBRINOLYTIC AGENT; HEPARIN COFACTOR II; PLASMA PROTEIN; PROTEIN COMPLEX C1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; COMPLEMENT SYSTEM; DISSOLUTION; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; IONIC STRENGTH; MALE; NONHUMAN; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; THROMBOSIS;

ACETYLGALACTOSAMINE; ANIMALS; ANTICOAGULANTS; CALCIUM; COMPLEMENT C1; DERMATAN SULFATE; FIBRINOLYTIC AGENTS; HEXOSAMINES; IDURONIC ACID; MALE; OSMOLAR CONCENTRATION; PRECIPITATION; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES;

EID: 2342638279     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.01.014     Document Type: Article

References (30)

1. Fareed J., Hoppensteadt D., Bick R. An update on heparins at the beginning of the new millennium. Semin. Thromb. Haemost. 26(1):2000;5-21
2. Doutremepuich C., Azougagh Oualane F., Doutremepuich F., Fareed J. New class of heparin derivates with a potent antithrombotic effect and a very limited hemorrhagic activity. Thromb. Res. 83(3):1996;217-228
3. Brigimshaw G.F., Shamberge J.N. Identification of two distinct heparin cofactors in human plasma. Separation and purification. Arch. Biochem. Biophys. 161:1974;683-690
4. Tollefsen D., Majerus D.W., Blank M.K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257:1982;2162-2169
5. Tollefsen D. Insight into the mechanism of action of heparin cofactor II. Thromb. Haemost. 74(5):1995;1209-1214
6. Bedayan P., Boccalon H., Dupouy D., Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb. Haemost. 71(5):1994;576-580
7. Cofrancesco E., Boschetti C., Leonardi F.G., Cortellaro M. Dematan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: a randomised, heparin-controlled pilot study. Thromb. Res. 7:1994;65-75
8. Di Carlo V., Agnelli G., Prandoni P., Coccheri S., Gensini G.F., Gianese F., et al. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. Thromb. Haemost. 82:1999;30-34
9. Fernández de Recondo M.E., Legorburu C., Monge J.C., Recondo E.F. Heparin and Concanavalin A interaction: isolation of a fraction with higher anticoagulant activity. Biochem. Biophys. Res. Commun. 155(1):1988;216-223
10. Monge J.C., Recondo E.F., Fernández de Recondo M.E. Heparin and Concanavalin A interaction as a model for studying the mechanism of the anticoagulant activity. Thromb. Res. 54:1989;237-243
11. Monge J.C., Legorburu C., Fernandez de Recondo M.E., Recondo E. Heparin and Concanavalin interaction: a useful model for study the mechanism of anticoagulant activity. Ann. N.Y. Acad. Sci. 556:1989;462-464
12. Fernandez de Recondo M.E., Monge J.C., Recondo E.F. Interaction of concanavalin A with a fraction of dermatan sulfate containing a very high anticoagulant activity. Cell. Mol. Biol. 41(4):1995;465-472
13. Calabrese G.C., Recondo M.M., Fernández de Recondo M.E., Recondo E.F. The first component of the human complement system recognizes the active fraction of heparin. Cell. Mol. Biol. 43(2):1997;237-242
14. Calabrese G.C., Leocata Nieto F., Recondo E.F., Fernandez de Recondo M.E. An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system. Cell. Mol. Biol. 47(17):2001;127-131
15. Calabrese G.C., Recondo E.F., Fernández de Recondo M.E. Antithrombin and first complement protein recognize the same active heparin fraction. Thromb. Res. 105:2002;537-541
16. Bing D. Purification of the first component of human complement by affinity chromatography on human gamma globulin linked to sepharose. J. Immunol. 107(5):1971;1243-1249
17. Bing D. Nature of active site of a subunit of the first component of human complement. Biochemistry. 8(11):1969;4503-4509
18. Sie P., Dupouy D., Pichon J., Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet. 24:1985;414-416
19. Twlikki T., Terho T., Hartiala K. Method for determination of the sulfate content of glycosaminoglycans. Anal. Biochem. 41:1971;471-476
20. Pavao M., Aiello K., Werneck C., Silva L., Valente A.P., Mulloy B., et al. Highly sulfated dermatan sulfates from ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J. Biol. Chem. 273(43):1998;27848-27857
21. Tollefsen D.M., Pestka C.A., Monafo W. Activation heparin cofactor II by dermatan sulfate. J. Biol. Chem. 258(11):1983;6713-6716
22. Griffith M.J., Marbet G.A. Dermatan Sulfate and Heparin can be fractionated by affinity for Heparin II Cofactor. Biochem. Biophys. Res. Commun. (112):1983;663-670
23. Tollefsen D.M., Peacock M.E., Monafo W.J. Molecular size of dermatan sulfate oligosaccharides required two bind an activate Heparin cofactor II. J. Biol. Chem. (261):1986;8854-8858
24. Maimone M., Tollefsen D.M. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J. Biol. Chem. 265(39):1990;18263-18271
25. Lindahl U. Lane D.A., Lindahl U. Heparin: chemical and biological properties, clinical applications. 1989;159-189 Edward Arnold, London
26. Lam L.H., Silbert J.E., Rosenberg R.D. The separation of active and inactive formas of heparin. Biochem. Biophys. Res. Comm. 69(2):1976;570-577
27. Griffith M.J. Heparin-catalyzed inhibitor/proteases reactions: kinetic evidence for common mechanism of action of heparin. Proc. Natl. Acad. Sci. U. S. A. 80:1983;5460-5464
28. Ofosu F.A., Modi G.J., Blajchman M.A., Buchanan M.R., Johnson E.A. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochem. J. 248:1987;889-896
29. Scully M.F., Seno E.N., Kakkar V.V. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. Biochem. J. 254:1988;547-551
30. Andoniades S.E., Schenone M., Recondo E.F., y Fernández de Recondo M.E. Influencia del grado de sulfatación en la actividad biológica del dermatan sulfato y del condroitin sulfato C. J. Arg. Chem. Soc. 90(1/3):2002;21-26